More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment

A post hoc time-to-control analysis of LixiLan-O and LixiLan-L

Juan Frias, Manuel Puig Domingo, Luigi Meneghini, Raffaele Napoli, Minzhi Liu, Erika Soltes Rak, Vanita R. Aroda

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The present post hoc analysis of two 30-week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan-O trial) or basal insulin (LixiLan-L trial). Time to control, defined as days to achieve glycated haemoglobin (HbA1c) <53 mmol/mol (<7%) or fasting plasma glucose (FPG) ≤7.2 mmol/L, was estimated using the Kaplan–Meier method. In the LixiLan-O and LixiLan-L trials, 60% and 46% of patients, respectively, reached HbA1c <53 mmol/mol (<7%) with iGlarLixi at 12 weeks, vs 45% and 24%, respectively, with iGlar. In the LixiLan-O trial, the median time to target HbA1c was approximately half with iGlarLixi vs iGlar (85.0 vs 166.0 days; P <.0001). In the LixiLan-L trial, the median time to target HbA1c was 153.0 days with iGlarLixi, while target HbA1c was never reached by 50% of patients with iGlar (P <.0001). Time-to-target FPG and hypoglycaemia outcomes were similar between treatments. In T2D uncontrolled on OADs or basal insulin, iGlarLixi resulted in glycaemic control in more patients than did iGlar at early treatment time points.

Original languageEnglish (US)
Pages (from-to)2314-2318
Number of pages5
JournalDiabetes, Obesity and Metabolism
Volume20
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Insulin
Therapeutics
Hypoglycemia
Type 2 Diabetes Mellitus
Fasting
ZP10A peptide
Insulin Glargine
Glucose
Glycosylated Hemoglobin A
Hypoglycemic Agents
Clinical Trials

Keywords

  • GLP-1
  • glycaemic control
  • insulin therapy
  • type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment : A post hoc time-to-control analysis of LixiLan-O and LixiLan-L. / Frias, Juan; Puig Domingo, Manuel; Meneghini, Luigi; Napoli, Raffaele; Liu, Minzhi; Soltes Rak, Erika; Aroda, Vanita R.

In: Diabetes, Obesity and Metabolism, Vol. 20, No. 9, 01.09.2018, p. 2314-2318.

Research output: Contribution to journalArticle

@article{c91d2bb39d584c0daeb83b39b8912278,
title = "More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L",
abstract = "The present post hoc analysis of two 30-week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan-O trial) or basal insulin (LixiLan-L trial). Time to control, defined as days to achieve glycated haemoglobin (HbA1c) <53 mmol/mol (<7{\%}) or fasting plasma glucose (FPG) ≤7.2 mmol/L, was estimated using the Kaplan–Meier method. In the LixiLan-O and LixiLan-L trials, 60{\%} and 46{\%} of patients, respectively, reached HbA1c <53 mmol/mol (<7{\%}) with iGlarLixi at 12 weeks, vs 45{\%} and 24{\%}, respectively, with iGlar. In the LixiLan-O trial, the median time to target HbA1c was approximately half with iGlarLixi vs iGlar (85.0 vs 166.0 days; P <.0001). In the LixiLan-L trial, the median time to target HbA1c was 153.0 days with iGlarLixi, while target HbA1c was never reached by 50{\%} of patients with iGlar (P <.0001). Time-to-target FPG and hypoglycaemia outcomes were similar between treatments. In T2D uncontrolled on OADs or basal insulin, iGlarLixi resulted in glycaemic control in more patients than did iGlar at early treatment time points.",
keywords = "GLP-1, glycaemic control, insulin therapy, type 2 diabetes",
author = "Juan Frias and {Puig Domingo}, Manuel and Luigi Meneghini and Raffaele Napoli and Minzhi Liu and {Soltes Rak}, Erika and Aroda, {Vanita R.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1111/dom.13368",
language = "English (US)",
volume = "20",
pages = "2314--2318",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment

T2 - A post hoc time-to-control analysis of LixiLan-O and LixiLan-L

AU - Frias, Juan

AU - Puig Domingo, Manuel

AU - Meneghini, Luigi

AU - Napoli, Raffaele

AU - Liu, Minzhi

AU - Soltes Rak, Erika

AU - Aroda, Vanita R.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The present post hoc analysis of two 30-week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan-O trial) or basal insulin (LixiLan-L trial). Time to control, defined as days to achieve glycated haemoglobin (HbA1c) <53 mmol/mol (<7%) or fasting plasma glucose (FPG) ≤7.2 mmol/L, was estimated using the Kaplan–Meier method. In the LixiLan-O and LixiLan-L trials, 60% and 46% of patients, respectively, reached HbA1c <53 mmol/mol (<7%) with iGlarLixi at 12 weeks, vs 45% and 24%, respectively, with iGlar. In the LixiLan-O trial, the median time to target HbA1c was approximately half with iGlarLixi vs iGlar (85.0 vs 166.0 days; P <.0001). In the LixiLan-L trial, the median time to target HbA1c was 153.0 days with iGlarLixi, while target HbA1c was never reached by 50% of patients with iGlar (P <.0001). Time-to-target FPG and hypoglycaemia outcomes were similar between treatments. In T2D uncontrolled on OADs or basal insulin, iGlarLixi resulted in glycaemic control in more patients than did iGlar at early treatment time points.

AB - The present post hoc analysis of two 30-week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan-O trial) or basal insulin (LixiLan-L trial). Time to control, defined as days to achieve glycated haemoglobin (HbA1c) <53 mmol/mol (<7%) or fasting plasma glucose (FPG) ≤7.2 mmol/L, was estimated using the Kaplan–Meier method. In the LixiLan-O and LixiLan-L trials, 60% and 46% of patients, respectively, reached HbA1c <53 mmol/mol (<7%) with iGlarLixi at 12 weeks, vs 45% and 24%, respectively, with iGlar. In the LixiLan-O trial, the median time to target HbA1c was approximately half with iGlarLixi vs iGlar (85.0 vs 166.0 days; P <.0001). In the LixiLan-L trial, the median time to target HbA1c was 153.0 days with iGlarLixi, while target HbA1c was never reached by 50% of patients with iGlar (P <.0001). Time-to-target FPG and hypoglycaemia outcomes were similar between treatments. In T2D uncontrolled on OADs or basal insulin, iGlarLixi resulted in glycaemic control in more patients than did iGlar at early treatment time points.

KW - GLP-1

KW - glycaemic control

KW - insulin therapy

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85051240947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051240947&partnerID=8YFLogxK

U2 - 10.1111/dom.13368

DO - 10.1111/dom.13368

M3 - Article

VL - 20

SP - 2314

EP - 2318

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 9

ER -